Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by TheBearInTheWoodson Jun 25, 2020 4:13pm

198 Views

Post# 31192285

RE: Today AGN will close at 0.25 ¢ depending on the L2 depth

Crazy close! its almost like I said the funds would raise the price to sell to retail! dont worry they will do this a couple more times as the price comes down becuase they litterally dont have a drug as per todays news release.

Also if you read the bottom of the news release they have a weak patent position and are trying to make a different type of the already generic drug...........

But yeah could have made a decent 20% today buying early and selling to horses before the brokers bailed.

Bullboard Posts

Three micro-cap value stocks trading at peak pessimism